Glenmark Pharmaceuticals has entered into a Strategic Development & Licensing Agreement with Celon Pharma S.A. to develop and market a generic version of GlaxoSmithKline’s Seretide Accuhaler® in Europe, enhancing its respiratory portfolio across key markets.

Target Information

Glenmark Pharmaceuticals, a prominent player in the generics market, is recognized for its diverse portfolio, which effectively balances oral solid and semi-solid products. The company has established a significant presence in Western Europe, focusing primarily on generics, driven by three key revenue streams: product distribution, dossier licensing, and the supply of finished dosage forms. The therapeutic areas that Glenmark emphasizes include dermatology, respiratory conditions, oncology, and cardiology. In addition to its successes in the UK and Germany, Glenmark is actively expanding into other key markets such as Spain, Denmark, Sweden, and Ireland.

In the Central and Eastern European regions, Glenmark boasts a portfolio comprising over 100 products, focusing on segments like central nervous system (CNS) disorders, respiratory health, cardiovascular issues, and metabolic conditions. Key markets in this geography include Poland, the Czech Republic, Slovakia, and Romania, which further enhances the company's reach and influence across Europe.

Industry Overview

The generics industry in Europe is characterized by robust growth driven by increasing healthcare costs and the need for affordable medication alternatives. As several blockbuster drugs lose patent protection, generic manufacturers are stepp